title: The interleukin-2 receptor: a target for immunotherapy.
authors: Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
authors: T A
authors: TA
authors: Waldmann
authors: C
authors: C
authors: Goldman
authors: L
authors: L
authors: Top
authors: A
authors: A
authors: Grant
authors: J
authors: J
authors: Burton
authors: R
authors: R
authors: Bamford
authors: E
authors: E
authors: Roessler
authors: I
authors: I
authors: Horak
authors: S
authors: S
authors: Zaknoen
authors: C
authors: C
authors: Kasten-Sportes
mesh_terms: D036002:ADP Ribose Transferases; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000276:immunology / Q000628:therapy*; D001427:Bacterial Toxins; D005098:Exotoxins / Q000008:administration & dosage / Q000627:therapeutic use; D005786:Gene Expression Regulation; D006084:Graft Rejection / Q000517:prevention & control; D016027:Heart Transplantation; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D000922:Immunotoxins / Q000627:therapeutic use; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000276:immunology / Q000628:therapy; D008213:Lymphocyte Activation; D008252:Macaca fascicularis; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D015202:Protein Engineering; D015375:Receptors, Interleukin-2 / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000737:chemistry / Q000502:physiology; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000627:therapeutic use; D013045:Species Specificity; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A
chemical_list: D036002:ADP Ribose Transferases; D000911:Antibodies, Monoclonal; D001427:Bacterial Toxins; D005098:Exotoxins; D000922:Immunotoxins; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A